A triple-drug therapy for pancreatic cancer has shown promise in early animal tests, pointing to a potential new treatment for a disease with a notoriously low survival rate.
Considered one of the deadliest common cancers, pancreatic cancer has a five-year relative survival rate around 13% — meaning roughly 87% of people with the cancer are expected to die within five years of diagnosis. That survival rate can plummet as low as 1% for people diagnosed in very late stages of the disease.
“These studies open a path to designing new combination therapies that can improve survival for patients with pancreatic ductal adenocarcinoma [the most common pancreatic cancer],” the study authors said in…




